Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Newbridge Financial Services Group Inc.

Newbridge Financial Services Group Inc. trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 27.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,101 shares of the company’s stock after selling 416 shares during the period. Newbridge Financial Services Group Inc.’s holdings in Moderna were worth $46,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. State Street Corp grew its holdings in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC grew its holdings in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Wellington Management Group LLP grew its holdings in Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after purchasing an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Down 2.9 %

Moderna stock opened at $30.93 on Wednesday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $39.77 and a two-hundred day moving average price of $56.76. The firm has a market capitalization of $11.90 billion, a price-to-earnings ratio of -5.31 and a beta of 1.59. Moderna, Inc. has a 52-week low of $30.70 and a 52-week high of $170.47.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Leerink Partners lowered their price target on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Jefferies Financial Group reduced their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. UBS Group reduced their price objective on shares of Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Bank of America reduced their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday. Finally, The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $66.89.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 2,664 shares of company stock valued at $115,210 in the last ninety days. Company insiders own 15.20% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.